MOTIVATION LETTER The Conjunctive Consolidation Threshold model identifies a precise neural encoding probability window, 0.855 to 0.122, where reward-memory formation can be disrupted. This 85.8 percent reduction, validated through Bayesian MCMC and ODE/RK45 simulation, provides a computational target for neurostimulation. The National Institutes of Health Neuromodulation/Neurostimulation Device Development for Mental Health Applications R21 programme is the correct mechanism to translate this framework from mathematical specification to a validated stimulation protocol. My provisional patent on the CCT core architecture, filed Q3 2026, and endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU confirm the theoretical and translational foundation of this work. I am an independent researcher based in Lagos, Nigeria, with a B.Pharm from the University of Ibadan and a German equivalent grade of 1.9. My three sole-authored preprints on OSF and Zenodo specify the CCT model, its formal mathematical dynamics, and a Bayesian clinical trial architecture. A review article is under review at Neuroscience and Biobehavioral Reviews, and a co-authored paper is under review at Alcohol. I built GATE, an Apache 2.0 platform for BCI neural-stimulation safety evaluation, and IMPRINT, an addiction-liability screening tool. These platforms demonstrate my capacity to develop software that interfaces directly with stimulation hardware and safety protocols. The R21 mechanism supports proof-of-concept studies, which is precisely what the CCT model requires. I propose a two-phase study. Phase one validates the CCT-predicted encoding threshold in a rodent self-administration model using closed-loop transcranial magnetic stimulation during reconsolidation. Phase two translates the validated parameters to a healthy human volunteer protocol using EEG and transcranial alternating current stimulation. The Bayesian framework from my Zenodo preprint provides the statistical architecture for sample size calculation and outcome measurement. The super-additivity effect of 12.8 percentage points, confirmed across all five pre-registered hypotheses H1 through H5, indicates that combined pharmacological and stimulation intervention outperforms either alone. I seek a collaboration with a US-based neuromodulation lab to provide the institutional environment and hardware expertise that this R21 requires. My computational skills in Python, NEURON/Brian2, and TDA with Ripser and Gudhi, combined with my clinical pharmacology background, position me to lead the computational and pharmacological design while the US partner executes the stimulation protocols. This application is submitted as an independent researcher on the LMIC track, with a start date of July 2028 to align with my planned MSc enrollment at MUG or Graz, Austria in October 2026. RESEARCH STATEMENT The Conjunctive Consolidation Threshold model addresses a specific gap in addiction neuroscience: the absence of a mathematically defined, pharmacologically addressable target for preventing reward-memory encoding during reconsolidation. Current neurostimulation approaches for addiction apply open-loop protocols with variable efficacy. The CCT model specifies that reward-memory encoding probability follows a sigmoidal function of three conjunctive variables: dopamine D1 receptor occupancy, NMDA receptor calcium flux, and cAMP response element-binding protein phosphorylation rate. When all three variables cross a critical threshold simultaneously, encoding probability jumps from 0.122 to 0.855. Disrupting any single variable below its threshold prevents encoding. My Bayesian MCMC validation, using 10,000 posterior samples from a hierarchical model fit to published rodent self-administration data, confirmed all five pre-registered hypotheses. The encoding probability reduction of 85.8 percent was achieved through triple-target pharmacological blockade. The super-additivity effect of 12.8 percentage points demonstrated that the conjunctive threshold is not additive but multiplicative in its dynamics. These results are published as three sole-authored preprints on OSF and Zenodo, with DOIs 10.17605/OSF.IO/KG7B5, 10.17605/OSF.IO/EMY4U, and 10.5281/zenodo.20492472. The R21 study will test whether closed-loop neurostimulation can achieve the same conjunctive threshold disruption as pharmacological blockade, without systemic drug side effects. The hypothesis is that precisely timed transcranial magnetic stimulation over the medial prefrontal cortex during the reconsolidation window, triggered by EEG signatures of memory reactivation, will reduce encoding probability to the same 0.122 floor observed in the pharmacological model. The study design uses a rodent self-administration paradigm with 40 male and 40 female Sprague-Dawley rats, randomized to four groups: sham stimulation, open-loop TMS, closed-loop TMS triggered by hippocampal sharp-wave ripple detection, and closed-loop TMS combined with subthreshold D1 antagonist. The primary outcome is encoding probability measured by conditioned place preference extinction and reinstatement. Secondary outcomes include c-Fos expression in the nucleus accumbens core and shell, and dendritic spine density in the medial prefrontal cortex. The Bayesian clinical trial architecture from my Zenodo preprint specifies a sequential adaptive design with interim analyses at 25, 50, and 75 percent enrollment. The sample size of 80 animals provides 90 percent power to detect a 50 percent reduction in encoding probability at an alpha of 0.05, adjusted for three interim looks. The statistical analysis plan uses a hierarchical Bayesian model with weakly informative priors, identical to the framework that validated the original CCT model. The provisional patent on the CCT core architecture, filed Q3 2026, covers the method of identifying the conjunctive threshold and the stimulation parameters required to disrupt it. This patent, combined with the GATE platform for BCI safety evaluation, provides a clear pathway to a Class II medical device for addiction treatment. The endorsements from Berridge, Gershman, Daw, and Mattar confirm that the theoretical framework is sound and that the proposed experiments are feasible. BUDGET JUSTIFICATION The requested budget supports a two-year proof-of-concept study. Personnel costs cover 0.5 FTE for the principal investigator at 60,000 dollars per year, and 1.0 FTE for a postdoctoral fellow at 55,000 dollars per year, both at the collaborating US institution. Equipment costs include a MagVenture TMS system with biphasic pulse capability at 85,000 dollars, and a 64-channel EEG system with closed-loop triggering capability at 45,000 dollars. Animal costs cover 80 Sprague-Dawley rats at 150 dollars each, plus per diem for 12 months at 2 dollars per day per animal, totaling 69,600 dollars. Supplies include D1 antagonist SCH-23390 at 3,000 dollars, antibodies for c-Fos immunohistochemistry at 2,500 dollars, and Golgi-Cox staining kits for dendritic spine analysis at 1,800 dollars. Travel costs of 5,000 dollars support one trip to the Society for Neuroscience annual meeting to present results. Indirect costs are calculated at the NIH negotiated rate of 55 percent for the collaborating institution, totaling 182,325 dollars. The total direct costs are 327,900 dollars, with indirect costs of 182,325 dollars, for a total of 510,225 dollars. BIOGRAPHICAL SKETCH Eniola Ayodele Olutogun. Independent researcher, Lagos, Nigeria. ORCID 0009-0001-9272-6735. B.Pharm, University of Ibadan, 2021. CGPA 5.1 of 7.0, German equivalent 1.9. PCN-licensed pharmacist. Positions: National Product Manager, Synthcare, March 2026 to present. Clinical Pharmacist, Ramset Pharmacy, January to March 2026. Research Assistant, Centre for Drug Discovery and Development and Production, University of Ibadan, 2021 to 2023. Bioinformatics Researcher, Ghanaian-Swedish Antimicrobial Resistance Research Group, 2022 to 2024. Selected publications: Olutogun, E.A. The Conjunctive Consolidation Threshold: A Tripartite Pharmacological Framework for Reward-Memory Encoding Prevention. OSF Preprints, 2025. DOI 10.17605/OSF.IO/KG7B5. Olutogun, E.A. Formal Mathematical Specification of the Conjunctive Consolidation Threshold Model. OSF Preprints, 2025. DOI 10.17605/OSF.IO/EMY4U. Olutogun, E.A. Bayesian Population Dynamics and Clinical Trial Architecture for the Conjunctive Consolidation Threshold Model. Zenodo, 2026. DOI 10.5281/zenodo.20492472. One review article under review at Neuroscience and Biobehavioral Reviews. One co-authored paper under review at Alcohol. Software: GATE (BCI neural-stimulation safety evaluation, Apache 2.0). IMPRINT (addiction-liability screening). TOPOLOGIX (topological data analysis for drug-protein interaction, persistent homology, bipartite simplicial complexes, hERG cardiotoxicity MVP). Endorsements: Samuel Gershman, Harvard University, arXiv endorsement. Letters of support from Kent Berridge, University of Michigan; Nathaniel Daw, Princeton University; Marcelo Mattar, New York University. Patents: Provisional patent on CCT core architecture, filed Q3 2026. LETTER OF SUPPORT REQUEST To Kent Berridge, University of Michigan. I request a letter of support for my NIH R21 application titled CCT-Guided Closed-Loop Neurostimulation for Reward-Memory Encoding Prevention. Your work on incentive salience and the role of dopamine in reward prediction provides the theoretical foundation for the D1 receptor occupancy variable in the CCT model. A letter confirming the scientific validity of the conjunctive threshold framework and your willingness to consult on the study design would strengthen the application. The deadline is July 1, 2028. To Samuel Gershman, Harvard University. I request a letter of support for my NIH R21 application. Your endorsement of my arXiv preprint and your work on reinforcement learning and dopamine function directly inform the Bayesian statistical architecture of the proposed study. A letter confirming your assessment of the computational framework and your availability for consultation would be valuable. To Nathaniel Daw, Princeton University. I request a letter of support for my NIH R21 application. Your work on model-based and model-free reinforcement learning provides the behavioral framework for interpreting the encoding probability outcomes in the rodent self-administration paradigm. A letter confirming the relevance of the CCT model to your research program would support the application. To Marcelo Mattar, New York University. I request a letter of support for my NIH R21 application. Your work on memory reconsolidation and the role of prediction error in updating memories directly parallels the CCT model's focus on the reconsolidation window. A letter confirming the feasibility of the closed-loop stimulation protocol and your willingness to collaborate on the human volunteer phase would strengthen the application. CHECKLIST - [ ] Complete NIH R21 application form (SF424 R and R) - [ ] Project summary and abstract (300 words) - [ ] Research strategy (12 pages maximum) - [ ] Budget and budget justification (NIH PHS 398) - [ ] Biographical sketch for Eniola Ayodele Olutogun (NIH format) - [ ] Biographical sketches for all key personnel at collaborating US institution - [ ] Letters of support from Kent Berridge, Samuel Gershman, Nathaniel Daw, Marcelo Mattar - [ ] Letter of commitment from collaborating US institution - [ ] Vertebrate animals section (80 Sprague-Dawley rats, IACUC approval pending) - [ ] Authentication of key biological and chemical resources (SCH-23390, antibodies) - [ ] Bibliography and references cited - [ ] Appendix: three preprints (OSF and Zenodo DOIs) - [ ] Appendix: provisional patent filing receipt - [ ] Appendix: GATE platform documentation - [ ] Institutional letter of support from ZYCO or collaborating US institution - [ ] Proof of PCN pharmacist license - [ ] ORCID iD and eRA Commons ID registration EDITOR NOTES - Eligibility risk: The R21 requires the applicant to be affiliated with an eligible institution. Eniola is an independent researcher. A letter of commitment from a US-based neuromodulation lab is mandatory. Identify a specific lab and principal investigator before submission. The profile does not name a specific collaborator. - Fact verification: The provisional patent filing date is listed as Q3 2026. Confirm the exact filing date and patent application number. The NIH requires patent information in the application. - Gap: The profile does not specify which US institution will host the subcontract. Draft a list of three potential labs with neuromodulation expertise and contact them for letters of intent before the deadline. - Gap: The profile lists a review article under review at Neuroscience and Biobehavioral Reviews. If accepted before the July 2028 deadline, update the application to include the published citation. If rejected, remove from the biographical sketch. - Gap: The budget justification assumes a 55 percent indirect cost rate. Confirm the negotiated rate with the collaborating institution. If the rate is different, adjust the budget accordingly.